Preclinical Efficacy and Immunological Safety of FR104, an Antagonist Anti-CD28 Monovalent Fab′ Antibody

Abstract : Antagonist anti-CD28 antibodies prevent T cell cos-timulation and differentiate from CTLA4Ig since they cannot block CTLA-4 and PDL-1 coinhibitory signals. They demonstrated efficacy in suppressing effector T cells while enhancing regulatory T cells function and immune tolerance. However, anti-CD28 antibodies devoid of immunotoxicity and with a good pharma-cokinetic profile have not yet been developed. Here, we describe FR104, a novel humanized pegylated anti-CD28 Fab antibody fragment presenting a long elimination half-life in monkeys. In vitro, FR104 failed to induce human T cell proliferation and cytokines secretion, even in the presence of anti-CD3 antibodies or when cross-linked with secondary antibodies. Furthermore , in humanized NOD/SCID mice adoptively transferred with human PBMC, whereas superagonist and divalent antibodies elicited rapid cytokines secretion and human T cell activation, FR104 did not. These humanized mice developed a florid graft-versus-host disease, which was prevented by administration of FR104 in a CTLA4-dependent manner. Interestingly, administration of high doses of CTLA4-Ig was ineffective to prevent GVHD, whereas administration of low doses was partially effective. In conclusion, we demonstrated that FR104 is devoid of agonist activity on human T cells and thus compatible with a clinical development that might lead to higher therapeutic indexes, by sparing CTLA-4, as compared to CD80/CD86 antagonists.
Document type :
Journal articles
Complete list of metadatas

Cited literature [65 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02167934
Contributor : Ana Paula Dutra Azevedo <>
Submitted on : Friday, June 28, 2019 - 12:04:27 PM
Last modification on : Friday, July 5, 2019 - 1:14:59 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

N. Poirier, C. Mary, N. Dilek, J. Hervouet, D. Minault, et al.. Preclinical Efficacy and Immunological Safety of FR104, an Antagonist Anti-CD28 Monovalent Fab′ Antibody. American Journal of Transplantation, Wiley, 2012, 12 (10), pp.2630-2640. ⟨10.1111/j.1600-6143.2012.04164.x⟩. ⟨inserm-02167934⟩

Share

Metrics

Record views

16